{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:35:29Z","timestamp":1787168129345,"version":"build-2736575974"},"reference-count":6,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Novel CAR-T therapies targeting delta-like ligand 3 (DLL-3) are promising treatment strategies for individuals with extensive-stage SCLC (ES-SCLC). We report a case of a patient with ES-SCLC who received investigational therapy LB2102 off-label after becoming ineligible for a clinical trial. We described her positive, long-term response to treatment. This case highlights efficacious use of this investigational drug in a real-world setting prior to release of final reported data from phase 1 trial NCT05680922.<\/jats:p>","DOI":"10.3389\/fonc.2026.1885732","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:22:15Z","timestamp":1783398135000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and efficacy of DLL3 CAR-T cells armored with dnTGFBR2 in a subject with recurrent small-cell lung cancer: case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Chelsey M.","family":"Williams","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, University of Kentucky Markey Cancer Center","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne M.","family":"Arnold","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, University of Kentucky Markey Cancer Center","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Villano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, University of Kentucky Markey Cancer Center","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika N. Amarilla","family":"Alonso","sequence":"additional","affiliation":[{"name":"University of Kentucky College of Medicine","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine F.","family":"Brainson","sequence":"additional","affiliation":[{"name":"Department of Toxicology and Cancer Biology, University of Kentucky Markey Cancer Center","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul O.","family":"Schwarzenberger","sequence":"additional","affiliation":[{"name":"Legend Biotech USA Inc.","place":["Somerset, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahista","family":"Vahora","sequence":"additional","affiliation":[{"name":"Legend Biotech USA Inc.","place":["Somerset, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Qasrawi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Cellular Therapy, University of Kentucky Markey Cancer Center","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhold","family":"Munker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Cellular Therapy, University of Kentucky Markey Cancer Center","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Mark","family":"Evers","sequence":"additional","affiliation":[{"name":"Department of Surgery, Markey Cancer Center, University of Kentucky Markey Cancer Center","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglin","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Medical Oncology, University of Kentucky Markey Cancer Center","place":["Lexington, KY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01435","article-title":"Systemic therapy for small-cell lung cancer: ASCO-Ontario Health (Cancer Care Ontario) guideline","volume":"41","author":"Khurshid","year":"2023","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00739-y","article-title":"Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms","volume":"8","author":"Serrano","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.07.026","article-title":"International real-world study of DLL3 expression in patients with small cell lung cancer","volume":"147","author":"Rojo","year":"2020","journal-title":"Lung Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-2845","article-title":"AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer","volume":"27","author":"Giffin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00553","article-title":"Sustained clinical benefit and intracranial activity of tarlatamab in previously treated small cell lung cancer: DeLLphi-300 trial update","volume":"42","author":"Dowlati","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1885732\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:22:16Z","timestamp":1783398136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1885732\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":6,"alternative-id":["10.3389\/fonc.2026.1885732"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1885732","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1885732"}}